Early carvedilol for heart failure shock
Part of Heart & circulation clinical trials.
This trial tests whether starting the heart failure medication carvedilol early, along with standard monitoring, can help people in cardiogenic shock (when the heart can't pump enough blood) due to a weak heart muscle. It aims to see if earlier treatment improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older, with no upper age limit.
- You have cardiogenic shock (your heart isn't pumping enough blood) and need care in an intensive care unit (ICU).
- You can take oral medication (pills by mouth).
- You are willing and able to give written informed consent, or have someone who can decide for you.
- You do not already have a mechanical heart pump or device for support.
- You have not had a recent heart attack (acute coronary syndrome) and do not have severe valve disease needing urgent surgery.
- You are not allergic to beta-blockers like carvedilol, and you have no asthma or bronchospasm history.
- You do not have a very slow heart rate, certain heart block problems, or sick sinus syndrome.
- You are not pregnant, within 30 days after childbirth, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a special pressure-monitoring tube in the heart’s main artery (a pulmonary artery catheter) helps people who are in cardiogenic shock from weak heart pumping. If you qualify, the goal is to improve how doctors monitor and treat this dangerous, fast-moving condition.
This trial studies whether doctors can safely reduce heart and blood-pressure support sooner in people with severe heart failure “shock.” It may help avoid side effects of strong medicines/devices while keeping the body’s organs well supported.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This trial tests whether using a temporary heart pump plus close monitoring improves recovery in people with severe heart failure after a heart attack, compared to standard care.
This trial is testing a temporary heart pump device that helps your heart pump blood when it's too weak to do its job. It's for people who have severe heart failure (cardiogenic shock) despite getting powerful medications to keep their heart working.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.